MAA

MAA Appoints Brad Hill to President and Chief Investment Officer

Retrieved on: 
Wednesday, December 13, 2023
Acquisition, Tulane University, NYSE, Cox School of Business, MAA, Culture, SMU, Trust, Urban Land Institute, Growth, Information technology, Business, NMHC, Management

GERMANTOWN, Tenn., Dec. 13, 2023 /PRNewswire/ -- Mid-America Apartment Communities, Inc., ("MAA") (NYSE: MAA) a leading multifamily real estate investment trust, announced today that A. Bradley Hill, 47, has been promoted to the role of President and Chief Investment Officer.

Key Points: 
  • GERMANTOWN, Tenn., Dec. 13, 2023 /PRNewswire/ -- Mid-America Apartment Communities, Inc., ("MAA") (NYSE: MAA) a leading multifamily real estate investment trust, announced today that A. Bradley Hill, 47, has been promoted to the role of President and Chief Investment Officer.
  • Mr. Hill joined MAA in 2010 and has over 20 years of real estate experience in the areas of transactions, development, and operations.
  • Mr. Hill has most recently served as Executive Vice President and Chief Investment Officer with oversight of the company's transactions and development operations.
  • Commenting on the appointment, Eric Bolton, Chairman and CEO, said "Brad has been a strong leader and performer throughout his 13-year career with MAA.

Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition

Retrieved on: 
Friday, December 8, 2023
NYSE, BLA, ASH, Acute myeloid leukemia, MAA, Cellular, Patient, CD33, Survival, CD45, Transplant, AML, Society, TP53, Actinium

Sandesh Seth, Actinium's Chairman & CEO, said, "We are particularly excited for this year's ASH as our four presentations will highlight the differentiated capabilities of Iomab-B and Actimab-A.

Key Points: 
  • Sandesh Seth, Actinium's Chairman & CEO, said, "We are particularly excited for this year's ASH as our four presentations will highlight the differentiated capabilities of Iomab-B and Actimab-A.
  • Better treatment options and outcomes are needed in AML, particularly for elderly patients and those with relapsed or refractory disease who represent a majority of the population.
  • Our strong presence at ASH is indicative of the potential that our targeted radiotherapies have in the management of patients with difficult to treat AML.
  • Details of Actinium's presentations at ASH are as follows:
    Room: Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19
    Session Name: 616.

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

Retrieved on: 
Thursday, November 30, 2023
Medicine, Food and Drug Administration, Bone marrow, Acquisition, NYSE, Food, Ovarian cancer, ADC, MAA, Patient, IMGN, ImmunoGen, European, EPS, FDA, Goldman Sachs, Morgan Stanley, AbbVie, Ropes & Gray, Cancer, Mirvetuximab soravtansine, Death, Survival, BPDCN, ABBV, PROC, Biologics license application, Lazard, Vaccine, Bank, Pharmaceutical industry, Financial adviser, Spacecraft

Under the terms of the transaction, AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 per share in cash.

Key Points: 
  • Under the terms of the transaction, AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 per share in cash.
  • "Together, AbbVie and ImmunoGen have the potential to transform the standard of care for people living with cancer."
  • As a fast-growing solid tumor therapy, ELAHERE provides AbbVie with a potential multi-billion-dollar on-market medicine with expansion opportunities in earlier lines of therapy and larger segments of the ovarian cancer market.
  • ImmunoGen's Phase 1 asset, IMGN-151, is a next-generation anti-FRα ADC for ovarian cancer with the potential for expansion into other solid tumor indications.

Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application

Retrieved on: 
Wednesday, November 22, 2023
Glioblastoma, QC, MHRA, MAA, Medication, Biotechnology, OTCQB, Northwest Biotherapeutics, Marketing, Risk management

BETHESDA, Md., Nov. 22, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma.

Key Points: 
  • BETHESDA, Md., Nov. 22, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma.
  • That team is now under way on this final stage of their work.
  • As described in the Company's prior update, it is anticipated that the publisher/QC team will need several weeks to complete their work on both the last portion of the MAA package and the integrated whole.
  • Their work is independent of the Company.

Jeff Taylor of Mphasis Digital Risk Appointed To 3rd MBA Board Term To Help Keep Housing A Top Priority In Washington

Retrieved on: 
Monday, November 13, 2023
Policy, MAA, Warburg, CNBC, Fintech, Fox Business, Mortgage Bankers Association, Warburg Pincus, Federal, MBA, Baptist Health, Housing, Management

MAITLAND, Fla., Nov. 13, 2023 /PRNewswire/ -- Jeff Taylor, Founder and Managing Director of Mphasis Digital Risk, a 3,500-employee company specializing in loan quality due diligence and outsourced underwriting for America's top mortgage institutions, has been elected to a third term as a member of the Mortgage Bankers Association (MBA) Board of Directors.

Key Points: 
  • Mr. Taylor and the other members of the 39-member MBA board were sworn in at the 2023 Annual Convention & Expo in Philadelphia, held from October 15th to 18th.
  • Along with his fellow directors, Mr. Taylor will work to bring policymakers and regulators together with the mortgage industry to address such top housing priorities as increasing inclusion and affordability.
  • The Board of Directors sets the strategic direction for MBA and oversees management of the association's operations.
  • He also serves on the non-profit boards of The Baptist Health Foundation of South Florida and Virtual Enterprises International.

Applied Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Massachusetts General Hospital, FDA, Research, Insurance, Harvard Medical School, Heart failure, MAA, Ongo, Treatment, MD, Cardiology, European Medicines Agency, Diabetes, Chairperson, Doctor of Philosophy, ChromeOS, EASD, Quality of life, Symposium, KOL, U.S. FDA, EMA, European Association for the Study of Diabetes, Annual general meeting, NDA, Safety, Therapy, Diabetic cardiomyopathy, Investment, Patient, Advanz Pharma, Pharmaceutical industry, Birth control, SORD, Galactosemia

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • The Company expects topline data from the study in the fourth quarter of 2023.
  • Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics, presented the data in an oral Symposium entitled Diabetic Cardiomyopathy (DbCM): a severe complication of diabetes.
  • Cash and cash equivalents and short-term investments totaled $37.5 million as of September 30, 2023, compared with $30.6 million at December 31, 2022.
  • Net loss for the third quarter of 2023 was $42.4 million, or $0.47 per basic and diluted common share, compared to a net loss of $19.1 million, or $0.40 per basic and diluted common share, for the third quarter 2022.

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Retrieved on: 
Wednesday, November 8, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Survival, VEGF, TAK, RAS, PDUFA, Food, Colorectal Cancer Alliance, MAA, Priority, JAMA, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, Priority review, PMDA, Colorectal cancer, CRC, EMA, FACP, Cancer, Metastasis, Patient, Diagnosis, Vanderbilt University Medical Center, Pharmaceutical industry, Takeda, EU, Lancet

"There is a pressing need for new treatments for individuals with metastatic colorectal cancer, who have had limited options and continue to face poor outcomes.

Key Points: 
  • "There is a pressing need for new treatments for individuals with metastatic colorectal cancer, who have had limited options and continue to face poor outcomes.
  • “For far too long, healthcare providers and patients have had limited options when selecting a therapy for metastatic colorectal cancer.
  • The trials investigated FRUZAQLA plus best supportive care versus placebo plus best supportive care in patients with previously treated mCRC.
  • “Colorectal cancer is a highly heterogeneous disease, making it difficult to bring advancements to patients whose cancer has metastasized.

IMPORTANT MESSAGE TO NYMOX SHAREHOLDERS: NYMOX Cautions Against Unauthorized Improper Shareholder Meeting and Unauthorized Unregistered Solicitations

Retrieved on: 
Thursday, November 2, 2023
Supreme court, Supreme Court of California, Theft, MAA, TM, Person, Fraud, Cutler, Indian psychology, Zeta Sagittarii, Record, Bankruptcy, CFO, Confidentiality, State Bar of California, General counsel, Government, Communication, The central science, Private law, Security (finance), Pharmaceutical industry

The Nymox Board has been fully supported by the vast majority of voting shareholders of Nymox who have legally provided the Company with their full support.

Key Points: 
  • The Nymox Board has been fully supported by the vast majority of voting shareholders of Nymox who have legally provided the Company with their full support.
  • None of them ever disclosed their relationship in this entity to Nymox, which is a serious breach of their duties and obligations to Nymox shareholders.
  • Entering into that agreement could have exposed Nymox to liabilities, and would have dramatically harmed Nymox shareholders.
  • There is a great need for men throughout the world to have access to this treatment technology, which is unique.

IMPORTANT NOTICE: NYMOX Cautions Shareholders Not to Take Calls or Participate in Unauthorized Improper Shareholder Meeting

Retrieved on: 
Tuesday, October 31, 2023
Supreme court, Supreme Court of California, MAA, TM, Person, Cutler, Indian psychology, Zeta Sagittarii, Record, Bankruptcy, CFO, Confidentiality, State Bar of California, General counsel, Communication, The central science, Private law, Security (finance), Pharmaceutical industry

The Nymox Board has been fully supported by the vast majority of voting shareholders of Nymox who have legally provided the Company with their full support.

Key Points: 
  • The Nymox Board has been fully supported by the vast majority of voting shareholders of Nymox who have legally provided the Company with their full support.
  • None of them ever disclosed their relationship in this entity to Nymox, which is a serious breach of their duties and obligations to Nymox shareholders.
  • We have been informed by more than one individual that Lanham and 3-Month Riley have approached Nymox Shareholders in the past seeking investment in their separate company, not Nymox.
  • Entering into that agreement could have exposed Nymox to liabilities, and would have dramatically harmed Nymox shareholders.

Notice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder Meeting

Retrieved on: 
Friday, October 27, 2023
Supreme court, Supreme Court of California, MAA, TM, Person, Cutler, Zeta Sagittarii, Record, Bankruptcy, CFO, Confidentiality, State Bar of California, General counsel, Communication, The central science, Private law, Security (finance), Private investigator

The Nymox Board has been fully supported by the vast majority of voting shareholders of Nymox who have legally provided the Company with their full support.

Key Points: 
  • The Nymox Board has been fully supported by the vast majority of voting shareholders of Nymox who have legally provided the Company with their full support.
  • None of them ever disclosed their relationship in this entity to Nymox, which is a serious breach of their duties and obligations to Nymox shareholders.
  • We have been informed by more than one individual that Lanham and 3-Month Riley have approached Nymox Shareholders in the past seeking investment in their separate company, not Nymox.
  • Entering into that agreement could have exposed Nymox to liabilities, and would have dramatically harmed Nymox shareholders.